Search Results

Drug Development

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD).

April 21, 2021

·

4 min read

BioCapital

AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions

Building on previous progress in the NIH Blueprint Neurotherapeutics program, AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM)

September 11, 2019

·

6 min read

Business

AgeneBio Founder Dr. Michela Gallagher participates in the 2018 Milken Global Conference

AgeneBio Founder Dr. Michela Gallagher participated in a panel discussion at the Milken Global Conference Alzheimer’s Disease: Rewriting the Playbook.

April 30, 2018

·

4 min read

Press Releases

Mild Cognitive Impairment Market to Reach a CAGR of 4.02% during 2024-2034, Impelled by Non-Invasive Brain Stimulation Techniques

July 22, 2024

·

9 min read

BioCapital

AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer’s Disease

NIH awards an expected $16 million to support Phase 3 pivotal clinical trial of AGB-101, a once-a-day treatment to slow progression in Mild Cognitive Impairment due to Alzheimer’s disease.

October 9, 2018

·

4 min read

Drug Development

AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

- AGB101 is the first investigational therapeutic that targets the reduction of hippocampal overactivity. - The study evaluates both Primary and Secondary Endpoints to measure cognitive and functional efficacy. - Secondary imaging endpoints will include measures of neurodegeneration.

January 17, 2019

·

4 min read

Business

Dr. Michela Gallagher Wins Alzheimer’s Drug Discovery Foundation’s Prestigious Melvin R. Goodes Prize

- Prize recognizes Dr. Gallagher’s contributions in the field of Alzheimer’s research in academia and through her groundbreaking therapeutics company, AgeneBio

September 17, 2018

·

6 min read

BioCapital

AgeneBio To Receive Up To $10 Million In NIH Funding To Advance Program For Mild Cognitive Impairment Due To Alzheimer’s Disease

September 14, 2017

·

6 min read

Drug Development

AgeneBio Receives NIH Grant To Initiate Phase III HOPE4MCI Trial To Treat MCI Due To Alzheimer’s Disease

September 19, 2017

·

4 min read

BioCapital

AgeneBio To Present At BIO Investor Forum 2015

October 6, 2015

·

1 min read